Bal Pharma Limited has informed the Exchange regarding Resignation of Mr.Kotian Chittanand Damodar (DIN # 09613054) - Executive Director of the company w.e.f. May 16, 2025.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bal Pharma Limited has informed the stock exchanges that Mr. Kotian Chittanand Damodar (DIN 09613054) has resigned from his position as Whole-time Director (an Executive Director role) effective May 16, 2025. The company received his resignation letter on the same date, and he has confirmed there are no other material reasons for stepping down beyond what is stated in his resignation letter. The filing was made under SEBI LODR Regulation 30, with full details and the resignation letter enclosed as annexures. The Managing Director, Mr. Shailesh Siroya, remains in his role.
This is a routine board-level change where one Whole-time Director exits voluntarily without any disclosed governance concerns. For shareholders, the resignation removes one executive from the board, but the Managing Director continues, so day-to-day operations should not be materially affected. No immediate stock price impact is expected, though investors may watch for any replacement appointment in the coming months.